Skip to main content
NUTRITION 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session: Dietary Bioactives From Bench to Bedside (Poster Theater Flash Session 15)

(PTFS15-04-24) Phenolic Metabolite Profiling in Children's Plasma and Urine Following Short-Term Supplementation With Wild Blueberry Powder

Monday, July 1, 2024
12:12 PM – 12:16 PM CT
Location:  W185A-C

    Presenting Author(s)

  • ED

    Eva C. Diaz, MD (she/her/hers)

    Assistant Professor
    Arkansas Children's Nutrition Center
    Little Rock, Arkansas, United States

    Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

    • Co-Author(s)

  • LF

    Laura Felgus-Lavefve, PhD Student

    Graduate Research Assistant
    University of Arkansas
    San Jose, California, United States

  • Sean H. Adams, PhD, FTOS

    Professor & Vice Chair for Basic Research, Dept. of Surgery
    University of California, Davis, School of Medicine
    Davis, California, United States

  • LP

    Lexi B. Poole

    Arkansas Children's Nutrition Center, United States

  • MB

    Margaret Ballard

    Arkansas Children's Nutrition Center, United States

  • MK

    Matthew Keene

    Arkansas Children's Nutrition Center, United States

  • LH

    Luke Howard, PhD

    Professor
    University of Arkansas
    Fayetteville, Arkansas, United States

Objectives: Native blueberry derived polyphenols are not highly bioavailable in the blood circulation due to extensive conversion through phase II and microbial biotransformation. The purpose of this study was to characterize the metabolite profile of wild blueberry (WBB) derived polyphenols in children’s plasma and urine following supplementation.

Methods: Children 11 to 12 years old were randomized to consume placebo (PL, n = 12 ) or WBB (n = 12, 15 g) containing products, twice a day, for 5 days. On the 6th day, baseline fasting blood (EDTA) and urine samples were collected before participants consumed a single dose of the WBB (15 g) or placebo product. Hourly blood and urine samples were collected for 5 hours. Native and conjugated phenolic-derived metabolites (n = 35) were measured from acidified samples using ultraperformance liquid chromatography-tandem mass spectrometry multiple reaction monitoring (UPLC-MS/MS MRM). Urine osmolality was adjusted to 120 mOsm/kg H2O.

Results: In Plasma, 20 of 35 targeted metabolites, including derivatives of benzoic, phenylacetic, phenylpropanoic, cinnamic, and hippuric acids, along with phloroglucinaldehyde and epicatechin were identified. Hippuric acid was the predominant metabolite in the WBB group followed by benzoic acid in its conjugated form. AUC0-5h analysis showed higher concentrations of 13 compounds in the WBB group compared to PL, including free and conjugated forms of phloroglucinaldehyde, ferulic acid, and sinapic acid. In urine, 29 of 35 targeted compounds were found. Alongside catechin, epicatechin, and phloroglucinaldehyde, there were 8 benzoic acid derivatives, 6 phenylacetic acid derivatives, 2 phenylpropanoic derivatives, 7 cinnamic acid derivatives, and 3 hippuric acid derivatives detected. All urine compounds were significantly higher in the WBB vs PL group.

Conclusions: WBB supplementation yielded higher plasma and urine concentrations of targeted metabolites. The bioactivity of these metabolites needs further assessment.

Funding Sources: USDA-ARS Project 3092-51000-056-04A